PICOT promotes T lymphocyte proliferation by down-regulating cyclin D2 expression

Figure 2 High expression of PICOT and low expression of CCND2 correlate with poor patient survival in different types of human cancer. PICOT and CCND2 mRNA expression and cancer patients’ clinical data were derived from the Cancer Genome Atlas database. Patients were divided into high or low expression groups, using the maximally selected rank statistics that is implemented in the R package “survminer”. Survival of patients was visualized using the Kaplan–Meier estimator and the 5 years survival probability of lung adenocarcinoma and 2 years survival probability of pancreatic adenocarcinoma, esophageal carcinoma and glioblastoma multiforme were calculated and presented in the bar graph.